Twin Tree Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-1,200
Closed -$363K 1689
2025
Q2
$363K Sell
1,200
-26,400
-96% -$7.87M ﹤0.01% 1467
2025
Q1
$9.14M Buy
27,600
+2,400
+10% +$789K 0.02% 703
2024
Q4
$7.78M Buy
25,200
+22,200
+740% +$6.24M 0.01% 787
2024
Q3
$637K Sell
3,000
-2,300
-43% -$588K ﹤0.01% 1277
2024
Q2
$1.48M Sell
5,300
-116,900
-96% -$27.8M ﹤0.01% 1010
2024
Q1
$32.6M Buy
+122,200
New +$28.8M 0.07% 278
2023
Q3
Sell
-1,500
Closed -$347K 1403
2023
Q2
$347K Sell
1,500
-12,900
-90% -$3.49M ﹤0.01% 1080
2023
Q1
$3.49M Buy
+14,400
New +$3.92M 0.01% 809

Other funds holding MDGL

Twin Tree Management's MDGL Position: Q3 2025 in Review

Twin Tree Management sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2025, closing a stake of 336 shares — an estimated $102K sold.

Twin Tree Management first reported a position in MDGL in Q1 2019 and held it in 7 quarters. The position peaked at $8.09M in Q1 2024. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • Twin Tree Management reported no remaining Madrigal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Twin Tree Management sold 336 Madrigal Pharmaceuticals shares in Q3 2025, an estimated $102K.
  • Twin Tree Management first reported a position in Madrigal Pharmaceuticals in Q1 2019 and held it in 7 quarters.
  • Twin Tree Management's Madrigal Pharmaceuticals position peaked at $8.09M in Q1 2024.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on Twin Tree Management's 13F filing for Q3 2025, filed 13 Nov 2025.